Market Place
Sourcing Support
Solasia Announces Launch of Darvias® in Japan
22 Aug 2022 //
BUSINESSWIRE
Solasia Pharma: DARVIAS Injection 135mg Approved in Japan
19 Jun 2022 //
BUSINESSWIRE
Announcement of the matters to be resolved at the Ordinary General Meeting
21 Feb 2022 //
PRESS RELEASE
Solasia Announces Finance via Issuance of Unsecured Straight Bond and Warrant
14 Feb 2022 //
PRESS RELEASE
Consolidated Financial Results for the Fiscal Year Ended December 31, 2021
09 Feb 2022 //
PRESS RELEASE
Business Overview of Pipeline Products
09 Feb 2022 //
PRESS RELEASE
Solasia, Nippon Kayaku Partner in Japan for DARINAPARSIN (SP-02)
26 Oct 2021 //
BUSINESSWIRE
Solasia announces the filing of a new regulatory filing for DARINAPARSIN
30 Jun 2021 //
BUSINESSWIRE
Isofol enters licensing agreement with Solasia to develop arfolitixorin in Japan
12 Aug 2020 //
PRNEWSWIRE
Solasia reports +ve results from ph2 study of new anti-cancer drug, darinaparsin
15 Jun 2020 //
PHARMABIZ
Solasia Announces Positive Results of DARINAPARSIN in Pivotal Phase 2 Study
14 Jun 2020 //
BUSINESSWIRE
Solasia enters new license alliance with Maruho
11 Dec 2019 //
BIOSPECTRUMASIA
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.